

## Translational Lung Cancer Research, the 7<sup>th</sup> AME Journal indexed in SCIE

### Editorial Office

Editorial Office of Translational Lung Cancer Research, AME Publishing Company, Hong Kong, China

Correspondence to: Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Hong Kong, China. Email: editor@tlcr.org.

Submitted Oct 11, 2018. Accepted for publication Oct 11, 2018.

doi: 10.21037/tlcr.2018.10.05

View this article at: <http://dx.doi.org/10.21037/tlcr.2018.10.05>

We are delighted to share the great news received on Oct 11<sup>th</sup>, 2018 that *Translational Lung Cancer Research* (TLCR) is selected by Clarivate Analytics (former Thomson Reuters Intellectual Property and Science Business) for indexing in the following products:


- ❖ Science Citation Index Expanded (also known as SciSearch<sup>®</sup>);
- ❖ Journal Citation Reports/Science Edition.

TLCR is the 7<sup>th</sup> journal of AME Publishing Company included by SCIE (Figure 1), following the other six sister journals:

- (I) *Journal of Thoracic Disease* (jtd.amegroups.com);
- (II) *Translational Cancer Research* (tcr.amegroups.com);
- (III) *Annals of Translational Medicine* (atm.amegroups.com);
- (IV) *Hepatobiliary Surgery and Nutrition* (hbsn.amegroups.com);
- (V) *Quantitative Imaging in Medicine and Surgery* (qims.amegroups.com);
- (VI) *Annals of Cardiothoracic Surgery* (<http://www.annalscts.com/>).

What's more, TLCR is the first international journal devoted to closing the gap between "Bench and Bedside" in lung cancer and related thoracic diseases with Prof. Yilong Wu as the Honorary Editor-in-Chief, Prof. Yong Song, Prof. Caicun Zhou and Prof. Rafael Rosell as the Editors-in-Chief, as well as the vigorous backup of a strong editorial board (Figure 2).

Since its launch in March 2012, TLCR has grown step by step (Figure 3).



**Figure 1** *Translational Lung Cancer Research* with the special issue "Lung Cancer in Never Smokers" guest-edited by Prof. Adi F. Gazdar.

- ❖ March 2012, first launched;
- ❖ December 2012, highlighted in MDLinx;
- ❖ September 2013, covered by Medscape;
- ❖ May 2014, indexed by Chemical Abstract Service (CAS) Database;

**Honorary Editor-in-Chief****Yi-Long Wu**

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

**Editors-in-Chief****Yong Song, MD, PhD**

Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

**Caicun Zhou, MD, PhD**

Department of Oncology, Shanghai Pulmonary Hospital, Affiliated to Tongji University School of Medicine, Shanghai, China

**Rafael Rosell, MD, PhD**

Director, Cancer Biology & Precision Medicine Program Catalan Institute of Oncology; Germans Trias i Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain

**Associate Editors-in-Chief****Wenhua Liang, MD (Oncology)**

Thoracic oncology, the First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China

**Heather A. Wakelee, MD (Medical Oncology)**

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford Cancer Institute, CA, USA

**Wenzhao Zhong, MD, PhD (Biomarker)**

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

**Figure 2** The Honorary Editor-in-Chief, Editors-in-Chief, and Associate Editors-in-Chief of TLCR.

- ❖ December 2014, indexed by PubMed Central (PMC);
- ❖ October 2015, indexed by Scopus;
- ❖ January 2016, included in Emerging Sources Citation Index;
- ❖ October 2018, indexed by Science Citation Index Expanded

Its articles increased from 50 in the first year to now 687 in total (up to Jun 2018) (*Figure 4*).

Its citation is climbing in multiples (*Figure 5*).


Its readership is distributed to all over the world.

It's grateful to see so much progress in the past six years, and this is indispensable of the contribution from our devoted editorial board members and authors (*Figures 6, 7*).


Particularly, we would like to extend our heartfelt gratitude to another group of experts—our Guest Editors, who have been actively involved in the forefront of scientific research and clinical practice and devoted their precious time and effort to organize the high-quality focused issues to demonstrate the cutting-edge knowledge, techniques, and discussions in their professional fields to our readers (*Table 1*).

Moreover, there are still our Section Editors, Reviewers and Readers worldwide that we could not express our appreciation one by one.


To TLCR, the coverage by SCIE is a milestone in




**Figure 3** Important landmarks of TLCR's development since its launch.




**Figure 4** Numbers of articles published by TLCR since its launch (data collected up to Jun 2018).



**Figure 5** Citation. Data were collected from Web of Science™ core collection on Aug 23, 2018.



**Figure 6** TLCR's international Editorial Board.



**Figure 7** In total, 645 Corresponding Authors from 27 countries contributed to TLCR, with the majority from USA, China, Italy, and Spain (data updated on Aug 27, 2018).

**Table 1** List of Guest Editors and their focused issues

---

Vol 7, No 5 (October 2018): Malignant Pleural and Peritoneal Mesothelioma—Guest Editors: Paul Van Schil, Jan Van Meerbeeck
Vol 7, No 4 (August 2018): Lung Cancer in Never Smokers—Guest Editor: Adi F. Gazdar
Vol 7, No 3 (June 2018): Lung Cancer Screening—Guest Editors: Caroline Chiles, Reginald F. Munden
Vol 7, No 2 (April 2018): Proton Therapy in Non-small Cell Lung Cancer—Guest Editors: Ramesh Rengan, Jing Zeng
Vol 7, No 1 (February 2018): Small Cell Lung Cancer: New Models, Markers and Beyond—Guest Editor: Peter Ujhazy
Vol 6, No 6 (December 2017): Imaging- and blood-based biomarkers for lung cancer precision medicine—Guest Editor: Feng-Ming (Spring) Kong
Vol 6, No 5 (October 2017): Update on Pathology and Predictive Biomarkers of Lung Cancer—Guest Editor: Mari Mino-Kenudson
Vol 6, No 4 (August 2017): Current Knowledge and Future Perspectives on Circulating Tumor Cells in Lung Cancer—Guest Editors: Fiona Blackhall, Caroline Dive
Vol 6, No 3 (June 2017): Malignant Pleural Mesothelioma: Updates and New Directions—Guest Editor: Chuong D. Hoang
Vol 6, No 2 (Apr 2017): Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies—Guest Editors: Charles B. Simone II, Abigail T. Berman, Salma K. Jabbour
Vol 6, No 1 (Feb 2017): Small Pulmonary Nodules—Guest Editors: Yong Song, Tangfeng Lv, Matthijs Oudkerk
Vol 5, No 6 (Dec 2016): Emerging Treatment Options for Brain Metastases from Non-small Cell Lung Cancer—Guest Editors: Giulio Metro, Rita Chiari
Vol 5, No 5 (Oct 2016): Liquid Biopsy in Lung Cancer—Guest Editor: Miguel Ángel Molina-Vila
Vol 5, No 3 (June 2016): The role of Nurses and Allied Health Professionals in lung cancer and mesothelioma care—Guest Editor: John White
Vol 5, No 1 (Feb 2016): Small Cell Lung Cancer—Guest Editors: Niki Karachaliou, Daniela Morales-Espinosa
Vol 4, No 6 (December 2015): Lung Cancer Immunotherapy—Guest Editor: María González-Cao
Vol 4, No 5 (October 2015): Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care—Guest Editor: Edward S. Kim
Vol 4, No 4 (August 2015): Improving the Quality and Outcomes of Lung Cancer Care: An Interdisciplinary Approach—Guest Editor: Raymond U. Osarogiagbon
Vol 4, No 2 (April 2015): Molecular Genetics of Lung Cancer—Guest Editor: Wendy A. Cooper
Vol 3, No 6 (December 2014): Personalized Therapy in Lung Cancer—Guest Editors: Na Zhang, Wen-Zhao Zhong, Yi-Long Wu
Vol 3, No 5 (October 2014): the 14th Central European Lung Cancer Conference (CELCC)—Guest Editors: Robert Pirker, Caicun Zhou
Vol 3, No 3 (June 2014): 4th European Lung Cancer Conference (ELCC)—Guest Editor: Paul Van Schil
Vol 3, No 2 (April 2014): the 10th Congress of Spanish Lung Cancer Group I—Guest Editors: Rafael Rosell, Bartomeu Massuti, Niki Karachaliou
Vol 3, No 1 (February 2014): Immunotherapy in Lung Cancer—Guest Editor: Yasuhiko Nishioka
Vol 2, No 5 (October 2013): Management of Early Stage Non-Small Cell Lung Cancer—Guest Editor: Heather Wakelee
Vol 2, No 3 (June 2013): Lung Cancer Issue (II)—Guest Editors: Rafael Rosell, Niki Karachaliou
Vol 2, No 2 (April 2013): Lung Cancer Issue (I) —Guest Editors: Rafael Rosell, Niki Karachaliou

---

its development, but also it marks an inception of a new stage with more chances and challenges forward. We look forward to the continued international teamwork to build TLCR an invaluable publication serving our scientists, doctors, patients and students, and welcome more and more excellent international peers and colleagues to join this endeavor.

**Cite this article as:** Editorial Office. *Translational Lung Cancer Research*, the 7<sup>th</sup> AME Journal indexed in SCIE. *Transl Lung Cancer Res* 2018;7(5):609-613. doi: 10.21037/tlcr.2018.10.05

### **Acknowledgements**

None.

### **Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.